000910176 001__ 910176
000910176 005__ 20230123110658.0
000910176 0247_ $$2doi$$a10.1016/S0969-8051(22)00127-5
000910176 0247_ $$2ISSN$$a0969-8051
000910176 0247_ $$2ISSN$$a1872-9614
000910176 0247_ $$2Handle$$a2128/33020
000910176 037__ $$aFZJ-2022-03656
000910176 041__ $$aEnglish
000910176 082__ $$a570
000910176 1001_ $$0P:(DE-Juel1)180770$$aHoffmann, Chris$$b0$$eCorresponding author$$ufzj
000910176 1112_ $$a24th International Symposium on Radiopharmaceutical Sciences$$cNantes$$d2022-05-29 - 2022-06-03$$giSRS 2022$$wGermany
000910176 245__ $$a[18F]ALX5406: a brain-penetrating prodrug for GlyT1-specific PET imaging
000910176 260__ $$c2022
000910176 3367_ $$033$$2EndNote$$aConference Paper
000910176 3367_ $$2DataCite$$aOther
000910176 3367_ $$2BibTeX$$aINPROCEEDINGS
000910176 3367_ $$2DRIVER$$aconferenceObject
000910176 3367_ $$2ORCID$$aLECTURE_SPEECH
000910176 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1670589666_16256$$xAfter Call
000910176 520__ $$aObjectives ALX5407 (1) is a potent and selective inhibitor of glycine transporter type 1 (GlyT1) originallydeveloped for the treatment of certain neurologic disorders like cognitive decline or schizophrenia. While it didnot reach clinical trials, ALX5407 could provide a starting point for development of GlyT1-selective PET tracersand was previously radiolabeled with carbon-11, but no preclinical studies have been published so far. The aim ofthe present work was to prepare the 18F-labeled counterpart [18F]ALX5407 ([18F]1) as well as its methyl ester[18F]ALX5406 ([18F]2), and to subject both candidate tracers to a preclinical evaluation.Methods The radiolabeling precursor was prepared by asymmetric reduction of 4'-bromo-3-chloropropiophenoneinto the respective (R)-alcohol (97% ee), followed by etherification via Mitsunobu reaction with 4-phenylphenol(>95% ee), amination with sarcosine methyl ester and finally Miyaura borylation. The radiosynthesis wasperformed using the protocol for alcohol-enhanced Cu-mediated radiofluorination. To this end, a solution ofEt4NHCO3 in nBuOH (400 μL) was used to elute 18F– from a QMA anion exchange cartridge into a solution of theradiolabeling precursor and Cu(py)4(OTf)2 (30 μmol of each) in DMA (800 μL) and the reaction mixture washeated at 110 °C for 10 min under air to afford [18F]2. The latter was hydrolyzed with 6 M NaOH to give [18F]1.Both tracers were evaluated by in vitro autoradiography in rat brain slices, in vivo μPET imaging in healthy rats,and ex vivo radiometabolite analysis in rat brain tissue and blood.Results The precursor was obtained in 15% yield over four steps. [18F]1 and [18F]2 were prepared in a ready-touseform in radiochemical yields of 55±7% (n=8) and 62±5% (n=4) within 90120 min, respectively, with molaractivities of 14137 GBq/μmol. In vitro evaluations showed accumulation of [18F]1 in brain regions consistentwith the distribution pattern of GlyT1, but in vivo brain uptake of the probe was very low. In contrast, [18F]2showed no specific binding in brain slices, but rapidly crossed the blood brain barrier (BBB) and showed an invivo brain distribution pattern consistent with GlyT1 specific binding. Metabolite studies demonstrated rapidhydrolysis of [18F]2 to [18F]1 in rat brain tissue and blood (t1/2=12 min), confirming that it acts as a BBB-penetratingprodrug.Conclusion [18F]2 is a promising and readily available prodrug for preclinical PET imaging of GlyT1 in the brain.Figure
000910176 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000910176 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000910176 7001_ $$0P:(DE-Juel1)165360$$aEvcüman, Sibel$$b1
000910176 7001_ $$0P:(DE-Juel1)175142$$aNeumaier, Felix$$b2$$ufzj
000910176 7001_ $$0P:(DE-Juel1)185610$$aZlatopolskiy, Boris$$b3$$ufzj
000910176 7001_ $$0P:(DE-Juel1)132740$$aHumpert, Swen$$b4$$ufzj
000910176 7001_ $$0P:(DE-Juel1)131810$$aBier, Dirk$$b5$$ufzj
000910176 7001_ $$0P:(DE-Juel1)131824$$aHolschbach, Marcus$$b6$$ufzj
000910176 7001_ $$0P:(DE-Juel1)131847$$aSchulze, Annette$$b7$$ufzj
000910176 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b8$$ufzj
000910176 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b9$$ufzj
000910176 773__ $$0PERI:(DE-600)1498538-X$$a10.1016/S0969-8051(22)00127-5$$gVol. 108-109, p. S45 -$$x0969-8051$$y2022
000910176 8564_ $$uhttps://juser.fz-juelich.de/record/910176/files/iSRS_alx_abstract_chris_hoffmann_final.pdf$$yOpenAccess
000910176 909CO $$ooai:juser.fz-juelich.de:910176$$pdriver$$pVDB$$popen_access$$popenaire
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180770$$aForschungszentrum Jülich$$b0$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)175142$$aForschungszentrum Jülich$$b2$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)185610$$aForschungszentrum Jülich$$b3$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132740$$aForschungszentrum Jülich$$b4$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131810$$aForschungszentrum Jülich$$b5$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131824$$aForschungszentrum Jülich$$b6$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131847$$aForschungszentrum Jülich$$b7$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b8$$kFZJ
000910176 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b9$$kFZJ
000910176 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000910176 9141_ $$y2022
000910176 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000910176 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000910176 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000910176 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000910176 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-12$$wger
000910176 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUCL MED BIOL : 2021$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000910176 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-12
000910176 920__ $$lyes
000910176 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000910176 980__ $$aconf
000910176 980__ $$aVDB
000910176 980__ $$aUNRESTRICTED
000910176 980__ $$aI:(DE-Juel1)INM-5-20090406
000910176 9801_ $$aFullTexts